



Molecular Mechanisms and Novel Therapeutic Approaches for Eye Diseases

Guest Editor:

Dr. Kofi Asiedu

School of Optometry & Vision
Science, University of New South
Wales, Sydney, NSW 2052,
Australia

Deadline for manuscript
submissions:

30 September 2024

Message from the Guest Editor

Dear Colleagues,

This Special Issue, “Molecular Mechanisms and Novel Therapeutic Approaches for Eye Diseases”, will cover a selection of recent research topics, preclinical studies, experimental studies, and current review articles related to the pathomechanisms, etiopathological pathways and management of eye disease, with a special emphasis on ocular surface disease. It will also include papers exploring potential treatment measures to attenuate both anterior and posterior eye disease. Apart from inflammation, understanding several key factors in the pathogenesis of eye diseases (e.g., oxidative stress, neurodegeneration, and neovascularization) open doors to novel therapeutic approaches. The molecular bases of many ophthalmic diseases are often not known, especially for multifactorial diseases. This challenge serves as roadblock in the development of novel therapeutic agents, and represents a major challenge for eye care practitioners.

Dr. Kofi Asiedu
Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)